{
    "nct_id": "NCT03483103",
    "official_title": "A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)",
    "inclusion_criteria": "* Confirmation of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma of the following histology at relapse: diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS; de novo or transformed follicular lymphoma [tFL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple hit lymphoma [DHL/THL]), and follicular lymphoma Grade 3B per WHO 2016 classification\n* Previous treatment must include treatment with a single line of chemoimmunotherapy containing an anthracycline and a CD20-targeted agent\n* Subjects must be deemed ineligible for both high-dose chemotherapy and hematopoietic stem cell transplant (based on age, performance status and/or comorbidities) while also having adequate organ function for CAR T cell treatment.\n* Positron emission tomography (PET)-positive disease\n* Histological confirmation of diagnosis at last relapse. Enough tumor material must be available for central confirmation of diagnosis, otherwise a new tumor biopsy is mandated.\n* ECOG performance status of 0, or 1, or 2\n* Adequate vascular access for leukapheresis procedure (either peripheral line or surgically-placed line)\n* Subjects must agree to use appropriate contraception\n* Subjects must agree to not donate blood, organs, semen, and egg cells for usage in other individuals for at least 1 year following lymphodepleting chemotherapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)\n* History of another primary malignancy that has not been in remission for at least 2 years.\n* Previous treatment with CD19-targeted therapy, with the exception of prior lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatment\n* Active hepatitis B or hepatitis C infection at the time of screening\n* History of or active human immunodeficiency virus (HIV) infection at the time of screening\n* Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or lisocabtagene maraleucel administration\n* History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease\n* History or presence of clinically relevant CNS pathology\n* Pregnant or nursing women\n* Subject does not meet protocol-specified washout periods for prior treatments\n* Prior hematopoietic stem cell transplant\n* Progressive vascular tumor invasion, thrombosis, or embolism\n* Venous thrombosis or embolism not managed on stable regimen of anticoagulation\n* Uncontrolled medical, psychological, familial, sociological, or geographical conditions",
    "miscellaneous_criteria": ""
}